Developer docs
API playgroundTry for free, no card

Search company profiles

Bolt Biotherapeutics

Full company profile

uuid00007mv

Namestring
Bolt Biotherapeutics
Legal namestring
Bolt Biotherapeutics, Inc.
Websiteurl
boltbio.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) for the treatment of solid tumors. Founded in 2015 by Dr. Edgar G. Engleman of Stanford University and headquartered in Redwood City, California, the company has built a proprietary platform called Boltbody™ ISAC that combines tumor-targeting antibodies with proprietary next-generation TLR7/8 agonist payloads delivered via non-cleavable linkers. The platform is designed to activate myeloid cells locally within the tumor microenvironment, reprogramming it and generating durable adaptive anti-tumor immune responses with the potential for immunological memory.

The company's pipeline includes BDC-4182, a next-generation Claudin 18.2 ISAC currently in a Phase 1 dose-escalation trial for gastric and gastroesophageal junction cancer with initial data anticipated in Q3 2026; BDC-3042, a first-in-class Dectin-2 agonist antibody that completed Phase 1 dose-escalation in April 2025 with signals of anti-tumor activity in non-small cell lung cancer; and preclinical CEA ISAC and PD-L1 ISAC programs. A prior HER2 ISAC (BDC-1001) completed Phase 1/2 and informed the next-generation designs. The company has no commercial product revenue.

Bolt Biotherapeutics generates revenue through strategic partnerships rather than direct product sales. Its business model centers on upfront payments, equity investments, and milestone-based economics from collaborations. The Genmab partnership (June 2021) includes $10 million upfront, a $15 million equity investment, and potential milestones of up to $285 million per candidate across up to three bispecific ISAC programs. A second collaboration with Toray funds a Caprin-1 ISAC, and Piramal Pharma Solutions provides contract manufacturing. The company went public on NASDAQ under ticker BOLT in February 2021, has 51–100 employees, and as of March 31, 2026 held $23.9 million in cash funding operations into 2027. Customer segments are oncology patients (eventual end market) and pharmaceutical partners (current revenue source).

Short descriptiontext

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing Boltbody™ ISAC antibody conjugates that combine tumor-targeting antibodies with TLR7/8 agonists to treat solid tumors. It serves cancer patients via its pipeline (BDC-4182, BDC-3042) and pharma partners (Genmab, Toray).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, antibody drug conjugates, cancer immunotherapy platform, clinical-stage biopharmaceuticals, innate immune system therapies
Industry2 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-Oncology Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration and Partnership Revenue
TypeLicensing Royalties
Description

Bolt Biotherapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies. These include upfront payments, equity investments, and milestone payments tied to development, regulatory, and commercial achievements. The Genmab partnership includes $10 million upfront, $15 million equity investment, and potential milestones up to $285 million per candidate.

globenewswire.com
2Future Product Sales
TypeOne Time License
Description

Pre-commercial stage; the company is developing ISAC therapeutic candidates targeting solid tumors. Revenue will depend on successful clinical development, regulatory approval, and commercialization of pipeline candidates including BDC-4182 for gastric cancer.

stocktitan.net
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Boltbody™ ISAC Platform
Description

Proprietary Immune-Stimulating Antibody Conjugate platform technology that enables tumor-specific activation of the innate immune system

boltbio.com
Core offering1 text field

Bolt Biotherapeutics is a clinical-stage immuno-oncology company that develops proprietary Immune-Stimulating Antibody Conjugate (ISAC) therapeutics through its Boltbody™ platform. Its product candidates combine tumor-targeting antibodies with proprietary TLR7/8 immune-stimulating payloads to activate the innate immune system against solid tumors, with lead candidates BDC-4182 (claudin 18.2 ISAC) in Phase 1 and BDC-3042 (Dectin-2 agonist) with Phase 1 dose-escalation complete.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • BDC-4182 demonstrated dramatically more potency than BDC-1001 in preclinical assays
+4 more records
Product overview1 text field

Bolt Biotherapeutics is a clinical-stage immuno-oncology company that has developed the proprietary Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate) platform. The platform combines tumor-targeting antibodies with TLR7/8 immune-stimulating payloads to activate the innate immune system against cancer cells. The company's lead product candidate is BDC-4182, a next-generation ISAC targeting claudin 18.2 in Phase 1 trials for gastric and gastroesophageal cancers. Additional proprietary programs include BDC-3042 (Dectin-2 agonist antibody, Phase 1 complete), CEA ISAC, and PD-L1 ISAC (both preclinical). Bolt also collaborated with Genmab on bispecific ISACs and with Toray on a Caprin-1 ISAC. A prior HER2-targeting ISAC program (BDC-1001) informed next-generation development.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Toray
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Toray collaboration funds a Boltbody ISAC targeting Caprin-1 through early clinical development. This is one of two existing collaborations based on the Boltbody ISAC platform.

boltbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-02
Description

Genmab and Bolt Biotherapeutics partnered to develop bispecific immune-stimulating antibody conjugates (ISACs). The deal involves Genmab paying Bolt $10 million upfront, making a $15 million equity investment, and funding early development, with milestones of up to $285 million per candidate. The collaboration funds up to 3 bispecific Boltbody ISACs through early clinical development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-06-25
Description

Production agreement for antibody drug conjugate manufacturing. Piramal provides contract manufacturing services for Bolt's therapeutic candidates.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC developer using proprietary amanitin-based payload technology. Comparable as a small-cap clinical-stage ADC platform company with novel payload chemistry, similar in capital structure and partnership strategy to Bolt.

TypeBroad incumbent
Description

Major oncology antibody company and Bolt's strategic partner (bispecific ISACs). Relevant as both partner and broader incumbent in the bispecific antibody space, with a deep bench of approved and clinical-stage oncology antibodies that validate the antibody-conjugate market.

TypeBroad incumbent
Description

Pioneer in ADC development (Kadcyla, Elahere), now part of AbbVie. Serves as the broad incumbent benchmark for ADC technology validation; even though much larger, ImmunoGen's pipeline closely parallels the technical blueprint Bolt is pursuing with ISACs.

TypeDirect peer
Description

Clinical-stage ADC developer with proprietary payload and linker chemistry targeting solid tumors. Directly comparable to Bolt as a clinical-stage antibody-conjugate oncology company; both face the same translation risk from preclinical ADC platforms to solid-tumor efficacy and commercial viability.

TypeBroad incumbent
Description

ADC market leader (Adcetris, Padcev, Tukysa), now part of Pfizer. Establishes the commercial ADC playbook and validates the strategic value of platform ADC companies; relevant peer for any Bolt exit or partnership scenario.

6Innate Pharma
TypeEmerging player
Description

Clinical-stage immuno-oncology company developing innate immune system-based therapies, including NK cell engagers and TLR agonists. Closely aligned with Bolt's strategy of leveraging the innate immune system against solid tumors.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing bispecific antibodies and antibody-drug conjugates. Similar platform-based approach to Bolt with a focus on myeloid-engagement and tumor-targeting antibodies, including multiple clinical-stage oncology assets.

TypeEmerging player
Description

Clinical-stage oncology company developing antibody-drug conjugates and immunotoxins for difficult-to-treat cancers. Similar stage and biological-modality focus to Bolt, with comparable pipeline economics and partnership-driven business model.

TypeDirect peer
Description

Clinical-stage ADC and bispecific antibody developer using cell-free protein synthesis platform to engineer novel antibody conjugates. Direct comparable in technical approach (engineered antibody conjugates) and oncology focus, with parallel platform-partnership business model.

TypeDirect peer
Description

Clinical-stage oncology company developing Probody-based antibody therapeutics, including antibody-drug conjugates targeting tumor microenvironments. Comparable in approach (engineered antibodies with tumor-localized activity) and stage to Bolt's ISAC strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bolt Biotherapeutics

Immuno-Oncology Therapeuticsboltbio.com

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing Boltbody™ ISAC antibody conjugates that combine tumor-targeting antibodies with TLR7/8 agonists to treat solid tumors. It serves cancer patients via its pipeline (BDC-4182, BDC-3042) and pharma partners (Genmab, Toray).

What Bolt Biotherapeutics does

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) for the treatment of solid tumors. Founded in 2015 by Dr. Edgar G. Engleman of Stanford University and headquartered in Redwood City, California, the company has built a proprietary platform called Boltbody™ ISAC that combines tumor-targeting antibodies with proprietary next-generation TLR7/8 agonist payloads delivered via non-cleavable linkers. The platform is designed to activate myeloid cells locally within the tumor microenvironment, reprogramming it and generating durable adaptive anti-tumor immune responses with the potential for immunological memory.

The company's pipeline includes BDC-4182, a next-generation Claudin 18.2 ISAC currently in a Phase 1 dose-escalation trial for gastric and gastroesophageal junction cancer with initial data anticipated in Q3 2026; BDC-3042, a first-in-class Dectin-2 agonist antibody that completed Phase 1 dose-escalation in April 2025 with signals of anti-tumor activity in non-small cell lung cancer; and preclinical CEA ISAC and PD-L1 ISAC programs. A prior HER2 ISAC (BDC-1001) completed Phase 1/2 and informed the next-generation designs. The company has no commercial product revenue.

Bolt Biotherapeutics generates revenue through strategic partnerships rather than direct product sales. Its business model centers on upfront payments, equity investments, and milestone-based economics from collaborations. The Genmab partnership (June 2021) includes $10 million upfront, a $15 million equity investment, and potential milestones of up to $285 million per candidate across up to three bispecific ISAC programs. A second collaboration with Toray funds a Caprin-1 ISAC, and Piramal Pharma Solutions provides contract manufacturing. The company went public on NASDAQ under ticker BOLT in February 2021, has 51–100 employees, and as of March 31, 2026 held $23.9 million in cash funding operations into 2027. Customer segments are oncology patients (eventual end market) and pharmaceutical partners (current revenue source).

Bolt Biotherapeutics firmographics

Firmographics
Name
Bolt Biotherapeutics
Legal name
Bolt Biotherapeutics, Inc.
Website
https://boltbio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing Boltbody™ ISAC antibody conjugates that combine tumor-targeting antibodies with TLR7/8 agonists to treat solid tumors. It serves cancer patients via its pipeline (BDC-4182, BDC-3042) and pharma partners (Genmab, Toray).
Ownership category
akta.pro rank

Bolt Biotherapeutics industry classification

Industry
Product category
Immuno-Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Immuno-oncology therapeutics
  • Antibody drug conjugates
  • Cancer immunotherapy platform
  • Clinical-stage biopharmaceuticals
  • Innate immune system therapies

Where Bolt Biotherapeutics is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Bolt Biotherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain

Revenue model

  1. Collaboration and Partnership Revenue: Bolt Biotherapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies. These include upfront payments, equity investments, and milestone payments tied to development, regulatory, and commercial achievements. The Genmab partnership includes $10 million upfront, $15 million equity investment, and potential milestones up to $285 million per candidate.
  2. Future Product Sales: Pre-commercial stage; the company is developing ISAC therapeutic candidates targeting solid tumors. Revenue will depend on successful clinical development, regulatory approval, and commercialization of pipeline candidates including BDC-4182 for gastric cancer.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Bolt Biotherapeutics product offering

Product offering

Core offering

Bolt Biotherapeutics is a clinical-stage immuno-oncology company that develops proprietary Immune-Stimulating Antibody Conjugate (ISAC) therapeutics through its Boltbody™ platform. Its product candidates combine tumor-targeting antibodies with proprietary TLR7/8 immune-stimulating payloads to activate the innate immune system against solid tumors, with lead candidates BDC-4182 (claudin 18.2 ISAC) in Phase 1 and BDC-3042 (Dectin-2 agonist) with Phase 1 dose-escalation complete.

Product overview

Bolt Biotherapeutics is a clinical-stage immuno-oncology company that has developed the proprietary Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate) platform. The platform combines tumor-targeting antibodies with TLR7/8 immune-stimulating payloads to activate the innate immune system against cancer cells. The company's lead product candidate is BDC-4182, a next-generation ISAC targeting claudin 18.2 in Phase 1 trials for gastric and gastroesophageal cancers. Additional proprietary programs include BDC-3042 (Dectin-2 agonist antibody, Phase 1 complete), CEA ISAC, and PD-L1 ISAC (both preclinical). Bolt also collaborated with Genmab on bispecific ISACs and with Toray on a Caprin-1 ISAC. A prior HER2-targeting ISAC program (BDC-1001) informed next-generation development.

Differentiator

Problem solved

Functional benefit

Brands

  • Boltbody™ ISAC Platform: Proprietary Immune-Stimulating Antibody Conjugate platform technology that enables tumor-specific activation of the innate immune system

Quantifiable outcome

  • BDC-4182 demonstrated dramatically more potency than BDC-1001 in preclinical assays
  • +4 more outcomes

Companies that use Bolt Biotherapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Bolt Biotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Bolt Biotherapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • ToraycoreStrategic or Co-development Partner · 1 January 2023Toray collaboration funds a Boltbody ISAC targeting Caprin-1 through early clinical development. This is one of two existing collaborations based on the Boltbody ISAC platform.
  • GenmabcoreStrategic or Co-development Partner · 2 June 2021Genmab and Bolt Biotherapeutics partnered to develop bispecific immune-stimulating antibody conjugates (ISACs). The deal involves Genmab paying Bolt $10 million upfront, making a $15 million equity investment, and funding early development, with milestones of up to $285 million per candidate. The collaboration funds up to 3 bispecific Boltbody ISACs through early clinical development.
  • Piramal Pharma SolutionsminorStrategic or Co-development Partner · 25 June 2020Production agreement for antibody drug conjugate manufacturing. Piramal provides contract manufacturing services for Bolt's therapeutic candidates.

Scale indicators9 records

Recent moves7 records

Expansion highlights4 records

Bolt Biotherapeutics competitors and assessment

Company assessment

Direct peers

  • Heidelberg Pharma: Clinical-stage ADC developer using proprietary amanitin-based payload technology. Comparable as a small-cap clinical-stage ADC platform company with novel payload chemistry, similar in capital structure and partnership strategy to Bolt.
  • Mersana Therapeutics: Clinical-stage ADC developer with proprietary payload and linker chemistry targeting solid tumors. Directly comparable to Bolt as a clinical-stage antibody-conjugate oncology company; both face the same translation risk from preclinical ADC platforms to solid-tumor efficacy and commercial viability.
  • Sutro Biopharma: Clinical-stage ADC and bispecific antibody developer using cell-free protein synthesis platform to engineer novel antibody conjugates. Direct comparable in technical approach (engineered antibody conjugates) and oncology focus, with parallel platform-partnership business model.
  • CytomX Therapeutics: Clinical-stage oncology company developing Probody-based antibody therapeutics, including antibody-drug conjugates targeting tumor microenvironments. Comparable in approach (engineered antibodies with tumor-localized activity) and stage to Bolt's ISAC strategy.

Broad incumbents

  • Genmab: Major oncology antibody company and Bolt's strategic partner (bispecific ISACs). Relevant as both partner and broader incumbent in the bispecific antibody space, with a deep bench of approved and clinical-stage oncology antibodies that validate the antibody-conjugate market.
  • ImmunoGen (AbbVie): Pioneer in ADC development (Kadcyla, Elahere), now part of AbbVie. Serves as the broad incumbent benchmark for ADC technology validation; even though much larger, ImmunoGen's pipeline closely parallels the technical blueprint Bolt is pursuing with ISACs.
  • Seagen (Pfizer): ADC market leader (Adcetris, Padcev, Tukysa), now part of Pfizer. Establishes the commercial ADC playbook and validates the strategic value of platform ADC companies; relevant peer for any Bolt exit or partnership scenario.

Emerging players

  • Innate Pharma: Clinical-stage immuno-oncology company developing innate immune system-based therapies, including NK cell engagers and TLR agonists. Closely aligned with Bolt's strategy of leveraging the innate immune system against solid tumors.
  • MacroGenics: Clinical-stage immuno-oncology company developing bispecific antibodies and antibody-drug conjugates. Similar platform-based approach to Bolt with a focus on myeloid-engagement and tumor-targeting antibodies, including multiple clinical-stage oncology assets.
  • Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotoxins for difficult-to-treat cancers. Similar stage and biological-modality focus to Bolt, with comparable pipeline economics and partnership-driven business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Bolt Biotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bolt Biotherapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Bolt Biotherapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bolt Biotherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bolt Biotherapeutics

What does Bolt Biotherapeutics do?

Bolt Biotherapeutics is a clinical-stage immuno-oncology company that develops proprietary Immune-Stimulating Antibody Conjugate (ISAC) therapeutics through its Boltbody™ platform. Its product candidates combine tumor-targeting antibodies with proprietary TLR7/8 immune-stimulating payloads to activate the innate immune system against solid tumors, with lead candidates BDC-4182 (claudin 18.2 ISAC) in Phase 1 and BDC-3042 (Dectin-2 agonist) with Phase 1 dose-escalation complete.

Is Bolt Biotherapeutics a public or private company?

Bolt Biotherapeutics is a public company. It is classified as public and is currently operating.

When was Bolt Biotherapeutics founded?

Bolt Biotherapeutics was founded in 2015. It employs 11 to 50 people.

Where is Bolt Biotherapeutics based?

Bolt Biotherapeutics is headquartered in Redwood City, United States, in the North America region.

How does Bolt Biotherapeutics make money?

Two revenue lines are on record. Collaboration and Partnership Revenue is the primary driver. The others are future Product Sales.

Who are Bolt Biotherapeutics's main competitors?

Direct peers on record are Heidelberg Pharma, Mersana Therapeutics, Sutro Biopharma and CytomX Therapeutics. Broad incumbents are Genmab, ImmunoGen (AbbVie) and Seagen (Pfizer). Emerging players are Innate Pharma, MacroGenics and Pyxis Oncology.

Does Bolt Biotherapeutics have an API?

No public API is recorded for Bolt Biotherapeutics.

What industry is Bolt Biotherapeutics in?

Bolt Biotherapeutics's product category is Immuno-Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooBolt Biotherapeutics, Inc.: Q3 Earnings SnapshotBolt Biotherapeutics reported a third-quarter loss of $4.4 million, or $2.25 per share. Shares rose 8% year-to-date and hit $5.91 in final trading, up 26% over the past year.Investing.comCoastlands Capital LP buys $319,000 in Bolt Biotherapeutics stockCoastlands Capital LP, a 10% owner and director of Bolt Biotherapeutics, purchased 50,000 shares on November 9, 2026, for $319,000. The shares were bought at an average price of $6.38, with the stock trading at $6.40, up 38% over six months. The purchase brings the firm's indirect stake to 462,416 shares.Business & FinancialBolt Biotherapeutics To Participate In Upcoming ConferencesBolt Biotherapeutics will present at the Stifel 2026 Healthcare Conference on November 10, 2026, and attend the Jefferies Global Healthcare Conference in London. The company acquired Prana Therapies in October 2026 via a stock-for-stock reverse merger and a $120 million private placement, with up to $60 million more possible from warrant exercise. Its lead program, PRA-216, is in Phase 2 development.TradingViewBolt Biotherapeutics to Participate in Upcoming ConferencesBolt Biotherapeutics announced participation in two investor conferences, with CEO Sheila Gujrathi presenting at Stifel and Jefferies events in November 2026. The company acquired Prana Therapies in October 2026 via a stock-for-stock reverse merger and a $120 million private placement, with up to $60 million more possible from warrants. Its lead program, PRA-216, is in Phase 2 development for inflammatory diseases.Seeking AlphaBolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks TranscriptBolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger and announced a concurrent private placement of $120 million upfront, with up to $60 million more from warrants. The financing will support Prana's clinical programs, including Phase II proof-of-concept data for PRA-216 expected in 2027.PR Newswire$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)Monteverde & Associates PC, a class action firm, is investigating Bolt Biotherapeutics' merger with Prana Therapies. The firm, which has recovered millions for shareholders, is questioning whether the deal is fair. It invites shareholders to contact the firm for free information.Pulse 2.0Bolt Biotherapeutics Acquires Prana Therapies And Raises $120 Million To Advance PRA-216Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger and raised $120 million in a private placement. The financing could total $180 million with warrant exercise, funding operations through 2028. PRA-216 Phase 2 data is expected in 2027.The Pharma LetterBolt Biotherapeutics acquires Prana TherapiesBolt Biotherapeutics acquired Prana Therapies, a clinical-stage biotech developing half-life-extended multispecific antibodies. Prana's pipeline includes an IL-4Rα/TSLP bispecific antibody in Phase II for asthma, COPD, and atopic dermatitis, with a planned Phase II study in eosinophilic esophagitis.TradingViewBolt Biotherapeutics appoints Sheila Gujrathi as director and chief strategy officerBolt Biotherapeutics appointed Sheila Gujrathi as a Class II director and chief strategy officer, effective October 23, 2026, after the First Effective Time under the Merger Agreement. She is the founder and CEO of Prana Therapies, with extensive leadership and board experience in biotechnology and biopharmaceuticals.TradingViewBolt Biotherapeutics Completes Prana Merger Alongside $120 Million FinancingBolt Biotherapeutics completed its merger with Prana Therapies on October 23, 2026, issuing Prana equityholders common and Series D preferred shares. The company also agreed to sell $120 million of preferred shares and warrants in a private placement expected to close October 26, with full cash exercise of warrants potentially generating about $60 million. The transaction triggered a $4.5 million payment to terminate a lease amendment.